Archive · 27 May 2025
New Antibiotic Enters Final Trials to Fight Superbug Infections
Imagine tiny germs that cause nasty infections, like pneumonia, becoming super strong and not responding to medicine.
Scientists have been working on a new medicine called zosurabalpin to fight these germs.
This medicine is now entering the final testing phase, where they will give it to about 400 people around the world.
It works differently than older medicines, so the germs might not be able to resist it.
If it works, it could help save many lives, as infections from resistant germs are a big problem, causing millions of deaths each year.
The new medicine is being developed by a company called Roche, in partnership with Harvard University.
A new antibiotic, zosurabalpin, is entering phase 3 trials to combat drug-resistant Acinetobacter baumannii.
The trials will involve approximately 400 patients worldwide.
Zosurabalpin uses a novel mechanism that bacteria may not yet have resistance to.
Acinetobacter baumannii is recognized as an urgent threat by the CDC.
If successful, the drug could be ready for approval by the end of the decade.
- Who
- Roche, in collaboration with Harvard University, developed zosurabalpin to treat infections caused by Acinetobacter baumannii.
- What
- A new antibiotic, zosurabalpin, is entering phase 3 trials to combat the drug-resistant bacterium Acinetobacter baumannii.
- When
- Phase 3 trials are underway, with potential approval by the end of the decade.
- Where
- Worldwide, with trials involving approximately 400 patients.
- Why
- To combat drug-resistant bacteria and address the public health challenge of antimicrobial resistance.
- Drug Name
- Zosurabalpin
- Target Bacteria
- Acinetobacter baumannii
- Trial Stage
- Phase 3
- Developers
- Roche & Harvard University
- Approximate Patients in Trials
- 400
- Infections Targeted
- Hospital-acquired infections (e.g., pneumonia, sepsis)
- Approval Timeline
- End of the decade (potential)